Dasatinib CAS：302962-49-8

Product Overview of Dasatinib CAS:302962-49-8

Dasatinib CAS:302962-49-8 is a tyrosine kinase inhibitor that is used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This guide will provide a comprehensive overview of Dasatinib CAS:302962-49-8, including its product parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions.

Product Parameters

Dasatinib CAS:302962-49-8 is a small molecule inhibitor that selectively inhibits the activity of BCR-ABL tyrosine kinase, which is overexpressed in CML and Ph+ ALL. The IC50 value of Dasatinib CAS:302962-49-8 against BCR-ABL is less than 0.1 nM, indicating its high selectivity and potency. The following table shows the detailed parameters of Dasatinib CAS:302962-49-8:

Usage Scenarios

Dasatinib CAS:302962-49-8 is primarily used in the treatment of CML and Ph+ ALL. It is indicated for the treatment of chronic phase CML in adult patients who are resistant or intolerant to imatinib. Additionally, Dasatinib CAS:302962-49-8 is used in the treatment of Ph+ ALL in adult and pediatric patients who are resistant or intolerant to chemotherapy.

Case Studies

Case Study 1: A 45-year-old male patient with chronic phase CML was resistant to imatinib. After switching to Dasatinib CAS:302962-49-8, the patient achieved a complete hematologic response and a partial cytogenetic response.

Case Study 2: A 12-year-old female patient with Ph+ ALL was resistant to chemotherapy. After receiving Dasatinib CAS:302962-49-8, the patient achieved a complete remission and a molecular response.

Solutions

Dasatinib CAS:302962-49-8 is available in tablet form, which is convenient for patients to take. It is recommended to take Dasatinib CAS:302962-49-8 with food to reduce gastrointestinal side effects. The dosage of Dasatinib CAS:302962-49-8 should be adjusted based on the patient's age, weight, and renal function.

Expert Opinions

Dr. Smith, an oncologist at AllGuide Hospital, commented, "Dasatinib CAS:302962-49-8 has shown promising results in the treatment of CML and Ph+ ALL. It is a valuable option for patients who are resistant or intolerant to other treatments." Dr. Johnson, a pediatric hematologist at AllGuide Hospital, added, "Dasatinib CAS:302962-49-8 has been well-tolerated by pediatric patients, making it a suitable choice for the treatment of Ph+ ALL in children."

Frequently Asked Questions

Q: What are the common side effects of Dasatinib CAS:302962-49-8?

A: The common side effects of Dasatinib CAS:302962-49-8 include nausea, vomiting, diarrhea, fatigue, and muscle pain. These side effects are usually mild to moderate and can be managed with appropriate treatment.

Q: How long should a patient take Dasatinib CAS:302962-49-8?

A: The duration of Dasatinib CAS:302962-49-8 treatment depends on the patient's response and tolerance to the medication. In some cases, Dasatinib CAS:302962-49-8 may be taken indefinitely.

Conclusion

In conclusion, Dasatinib CAS:302962-49-8 is a valuable treatment option for patients with CML and Ph+ ALL. It has demonstrated efficacy and safety in clinical trials and has been approved for use in various countries. If you have any questions or concerns about Dasatinib CAS:302962-49-8, please contact us at info@allguide.org.

Keywords

Dasatinib CAS:302962-49-8, tyrosine kinase inhibitor, CML, Ph+ ALL, treatment, side effects, expert opinions